We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
+24.25%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.59B
AUM Growth
+$706M
Cap. Flow
-$31.5M
Cap. Flow %
-0.69%
Top 10 Hldgs %
73.61%
Holding
44
New
6
Increased
8
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
PBLS
Parabilis Medicines Inc
PBLS
+$53.1M
2
ALLO icon
Allogene Therapeutics
ALLO
+$41M
3
NAMS icon
NewAmsterdam Pharma
NAMS
+$37.7M
4
ACHV icon
Achieve Life Sciences
ACHV
+$36.3M
5
KLRA
Kailera Therapeutics
KLRA
+$24.2M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$133M
2
KALV
KalVista Pharmaceuticals
KALV
+$99.9M
3
RVMD icon
Revolution Medicines
RVMD
+$65.7M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$42.5M
5
TRVI icon
Trevi Therapeutics
TRVI
+$1.45K

Sector Composition

Rank Sector Weight
1 Healthcare 99.77%
2 Miscellaneous 0.23%

No holdings matched the selected filter criteria.

1 2

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q2 2026 Portfolio in Review

As of Q2 2026, Frazier Life Sciences Management held 44 positions worth $4.59B, up 18% from $3.89B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Frazier Life Sciences Management's Q2 2026 filing shows 6 new, 8 increased, 2 reduced and 3 closed positions. Its largest new stake was Parabilis Medicines Inc: 1,920,805 shares worth $52.6M. The largest sale was BridgeBio Pharma, an estimated $133M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

  • Frazier Life Sciences Management's largest Q2 2026 buy was Parabilis Medicines Inc: 1,920,805 shares worth $52.6M.
  • Frazier Life Sciences Management added most to Allogene Therapeutics in Q2 2026, an estimated $41M increase.
  • Frazier Life Sciences Management's biggest Q2 2026 reduction was BridgeBio Pharma, cutting an estimated $133M.
  • Frazier Life Sciences Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $99.9M.
  • Frazier Life Sciences Management's ten largest holdings make up 74% of its $4.59B portfolio in Q2 2026.
  • Frazier Life Sciences Management opened 6 new positions and closed 3 in Q2 2026.
  • Frazier Life Sciences Management's portfolio value rose 18% quarter-over-quarter to $4.59B.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.